文献速递儿童内分泌与遗传代谢儿童消化与营养

1型糖尿病患儿乳糜泻筛查:HLA基因分型是否合适?

Screening for coeliac disease in 1624 mainly asymptomatic children with type 1 diabetes: is genotyping for coeliac-specific human leucocyte antigen the right approach?
PubMed 文献 · Arch Dis Child · 2018-10-16

该多中心观察性分析基于德国、奥地利、瑞士和卢森堡439个中心的糖尿病前瞻性随访数据库,纳入1624例接受乳糜泻特异性HLA基因分型的1型糖尿病患儿。结果显示82.8%携带HLA-DQ2或HLA-DQ8,仅17.2%无乳糜泻特异性HLA标志物;26.6%的高危患者有临床疑似乳糜泻诊断,3.6%有活检证实的乳糜泻。结论认为HLA基因分型不適合作为一线筛查以排除乳糜泻,仍推荐定期筛查乳糜泻特异性抗体。

要点

  • 1型糖尿病患儿中82.8%携带乳糜泻特异性HLA-DQ2或HLA-DQ8。
  • 仅17.2%的1型糖尿病患儿无乳糜泻特异性HLA标志物。
  • HLA基因分型不宜作为一线筛查以排除乳糜泻,仍推荐定期抗体筛查。

核心结论

  • HLA-DQ2或HLA-DQ8在1型糖尿病患儿中阳性率超过80%,因此乳糜泻特异性HLA基因分型不适合作为一线筛查以排除乳糜泻。
  • 对1型糖尿病患儿仍推荐定期筛查乳糜泻特异性抗体。

研究设计与样本

  • 多中心观察性分析,数据来自德国、奥地利、瑞士和卢森堡439个中心的糖尿病前瞻性随访数据库。

主要发现

  • 1624例接受HLA基因分型的患者中,1344例(82.8%)为HLA-DQ2、HLA-DQ8或两者阳性,17.2%无乳糜泻特异性HLA标志物。
  • 26.6%的高危患者有临床疑似乳糜泻诊断,3.6%有活检证实的乳糜泻。

关键数值与推荐

  • HLA-DQ2、HLA-DQ8或两者阳性率在1型糖尿病患儿中为82.8%。
  • 无乳糜泻特异性HLA标志物的比例为17.2%。

临床怎么用

  • 不应将乳糜泻特异性HLA基因分型作为1型糖尿病患儿排除乳糜泻的一线筛查方法。
  • 应继续对1型糖尿病患儿定期筛查乳糜泻特异性抗体。

局限性

  • 摘要未报告HLA基因分型与抗体筛查或活检确诊之间的完整对比数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the frequency of coeliac disease (CD)-specific human leucocyte antigen (HLA) genotypes in paediatric patients with type 1 diabetes (T1D), who are known to have a higher prevalence of CD than the general population, and to evaluate whether HLA genotyping is a suitable first-line screening method for CD. STUDY DESIGN: The study was a multicentre observational analysis of patients with T1D aged <20 years of whom a subgroup had undergone HLA genotyping. Patient data were retrieved from the Diabetes Prospective Follow-up database, a large diabetes follow-up registry. The present analysis included data from 439 centres throughout Germany, Austria, Switzerland and Luxembourg. RESULTS: In March 2017, the database contained 75 202 patients with T1D (53% male, mean age (SD) 14.6 (4.1) years, mean age at diagnosis 8.8 (4.3) years and mean diabetes duration 5.8 (4.3) years). 1624 patients had undergone coeliac-specific HLA genotyping, of whom 1344 (82.8%) were positive for HLA-DQ2, HLA-DQ8 or both, while 17.2% had no coeliac-specific HLA-markers. 26.6% of at-risk patients had a clinical suspected diagnosis of CD, and 3.6% had biopsy-proven CD. CONCLUSIONS: Genotyping for HLA-DQ2, HLA-DQ8 or both is positive in the vast majority (>80%) of patients with T1D. Therefore, screening for coeliac-specific HLA genotypes as a first-line test is not a suitable method to exclude CD in T1D. Regular screening for coeliac-specific antibodies in T1D is still recommended.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Binder E, Rohrer T, Denzer C, et al. Screening for coeliac disease in 1624 mainly asymptomatic children with type 1 diabetes: is genotyping for coeliac-specific human leucocyte antigen the right approach? Arch Dis Child. 2018. PMID: 30327331. doi:10.1136/archdischild-2018-315549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。